Impact
Clinical work that changed systems.
Five years of building programs, changing policies, and measuring what actually matters.
$2M
Utilization Management Program
Designed and led a UM program delivering $2M in drug cost savings through a 5% reduction in utilization. Negotiated the contractual prescribing target from 15% down to 5% to preserve clinical outcomes and avoid downstream medical costs.
ADA
2026 Standards of Care
Submitted clinical findings on GLP-1 and DPP-4 inhibitor duplication to the American Diabetes Association. Their 2026 Standards of Care now include a statement directly addressing this duplication.
$236K
Polypharmacy Intervention Program
Validated $236,152 in combined savings across 40 provider interventions from October 2023 to March 2024, then advocated upstream to embed the fix at the prior authorization level — creating structural prevention before prescriptions are ever filled.
7
Health Plan Relationships
Built and maintained active monthly relationships with pharmacy teams across seven major health plans including Florida Blue and UnitedHealthcare — leading formulary education, PA redesign, and payer strategy discussions incorporating downstream medical cost offsets.
GLP-1
Patient Education and Policy Change
Developed dual-approved GLP-1 patient education materials and identified patients on non-therapeutic Mounjaro titration doses. Advocated with Florida Blue until coverage policy changed to ensure members advance to therapeutically effective doses.
60+
Clinics and 500K+ Members
Clinical protocols and educational resources deployed across 60+ Florida clinics, adopted as standard onboarding materials for all new providers and cross-functional teams across a 500,000+ member population.